Four magnetic resonance imaging surveillance-detected breast cancer cases in cancer-free BRCA1/2 mutation carriers

Takaoka, Megumi; Ohsumi, Shozo; Miyoshi, Yukiko; Takahashi, Mina; Takashima, S; Aogi, Kenjiro; Shimizu, T.; Teramoto, Norihiro; Yamamoto, Yorimasa; Okamura, Miki

doi:10.1186/s40792-021-01313-5

Cited by 2 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Risk-reducing surgery can thus be considered cancer preventive medicine in the true sense of the word. However, in Japan, risk-reducing surgery is not covered by health insurance for patients without cancer [7]. At our hospital, CRRM costs about 605,000 yen (including tax), RRSO costs 880,000 yen (including tax), and hysterectomy and ovarian salpingectomy costs 1,210,000 yen (including tax).…”

Section: Discussionmentioning

confidence: 96%

“…However, these bene ts are only available to those who have already developed breast or ovarian cancer, and the current situation is that HBOC medical care remains an out-of-pocket expense for those who have not developed cancer [7]. We report on a patient undergoing out-of-pocket surveillance as an undiagnosed (cancer-free) HBOC who was diagnosed with noninvasive breast cancer and was able to receive breast cancer treatment and risk-reducing surgery simultaneously under insurance coverage.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Concomitant cancer surgery and risk-reducing surgery for noninvasive breast cancer diagnosed during surveillance for undiagnosed hereditary breast and ovarian cancer (HBOC) syndrome: A case report

Tanaka

Matsumoto

Takao

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: In Japan, genetic testing, surveillance, and risk-reducing surgery for hereditary breast and ovarian cancer (HBOC) syndrome have been covered by the Japanese national insurance system since April 2020. On the other hand, the current situation is that medical care, including surveillance of undiagnosed (cancer-free) patients, is self-funded even for individuals with HBOC. We report a case in which breast cancer was diagnosed at an early stage during surveillance for cancer-free HBOC at the patient's own expense, and risk-reducing surgery was performed at the same time as treatment for breast cancer. Case presentation: The patient was a 63-year-old woman. Her sister had a history of breast cancer in her 30s and was found to be a BRCA2 pathogenic variant carrier by genetic testing. The patient therefore presented to the genetic department of our hospital and underwent genetic testing (out-of-pocket). A pathogenic variant was found at the same site. During annual breast and ovarian surveillance at the patient’s own expense, the physician with sufficient expertise in contrast-enhanced breast magnetic resonance imaging (MRI) noticed a change in the contrast enhancement pattern on breast MRI and performed needle biopsy, revealing ductal carcinoma in situ. At her request, she underwent concurrent contralateral risk-reducing mastectomy and risk-reducing salpingo-oophorectomy in addition to breast cancer treatment. Conclusions: We have seen a case in which cancer treatment and risk-reducing surgery were performed at the same time for a pathogenic variant carrier who was very anxious about developing cancer. Surveillance of cancer-free BRCA1/2 mutation carriers and expansion of insurance coverage for surgery are important future issues.

show abstract

Section: Discussionmentioning

confidence: 96%

mentioning

confidence: 99%

Concomitant cancer surgery and risk-reducing surgery for noninvasive breast cancer diagnosed during surveillance for undiagnosed hereditary breast and ovarian cancer (HBOC) syndrome: A case report

Tanaka

Matsumoto

Takao

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

Simultaneous bilateral mastectomy and RRSO for BRCA2-positive non-invasive breast cancer in Japan: a case report and analysis of initial experience

Tanaka,

Matsumoto,

Takao

et al. 2023

Hered Cancer Clin Pract

View full text Add to dashboard Cite

Background In Japan, genetic testing, surveillance, and risk-reducing surgery for hereditary breast and ovarian cancer (HBOC) syndrome have been covered by the Japanese national insurance system since April 2020. On the other hand, the current situation is that medical care, including surveillance of undiagnosed (cancer-free) patients, is self-funded even for individuals with HBOC. We report a case in which breast cancer was diagnosed at an early stage during surveillance for cancer-free HBOC at the patient’s own expense, and risk-reducing surgery was performed at the same time as treatment for breast cancer. Case presentation The patient was a 63-year-old woman. Her sister had a history of breast cancer in her 30s and was found to be a BRCA2 pathogenic variant carrier by genetic testing. The patient therefore presented to the genetic department of our hospital and underwent genetic testing (out-of-pocket). A pathogenic variant was found at the same site. During annual breast and ovarian surveillance at the patient’s own expense, a physician with sufficient expertise in contrast-enhanced breast magnetic resonance imaging (MRI) noticed a change in the contrast enhancement pattern on breast MRI and performed needle biopsy, revealing ductal carcinoma in situ. At the request of the patient, she underwent concurrent contralateral risk-reducing mastectomy and risk-reducing salpingo-oophorectomy in addition to breast cancer treatment. Conclusions We encountered a case in which cancer treatment and risk-reducing surgery were performed at the same time for a pathogenic variant carrier who was very anxious about developing cancer. Surveillance of cancer-free BRCA1/2 mutation carriers and expansion of insurance coverage for surgery are important future issues.

show abstract

Four magnetic resonance imaging surveillance-detected breast cancer cases in cancer-free BRCA1/2 mutation carriers

Cited by 2 publications

References 10 publications

Concomitant cancer surgery and risk-reducing surgery for noninvasive breast cancer diagnosed during surveillance for undiagnosed hereditary breast and ovarian cancer (HBOC) syndrome: A case report

Concomitant cancer surgery and risk-reducing surgery for noninvasive breast cancer diagnosed during surveillance for undiagnosed hereditary breast and ovarian cancer (HBOC) syndrome: A case report

Simultaneous bilateral mastectomy and RRSO for BRCA2-positive non-invasive breast cancer in Japan: a case report and analysis of initial experience

Contact Info

Product

Resources

About